Short answer
Septerna, Inc. (SEPN) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 results and business highlights announced for the quarter ended September 30, 2026.
Septerna, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results and business highlights announced for the quarter ended September 30, 2026
- Detailed financial figures and operating updates available in Exhibit 99.1 press release
- Investor focus: cash position, pipeline progress and development spending in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 revenue $18.9M, including $5.2M milestone revenue and $11.0M Novo research services
- Net loss $26.6M versus $8.2M net income, reflecting higher R&D expense of $36.6M
- Cash, equivalents and marketable securities $565.2M, supporting operations at least into mid-2029
- SEP-479 Phase 1 SAD/MAD data expected Q1 2027, the next key clinical catalyst
- SEP-204 Phase 1 trial planned for Q1 2027, expanding the pipeline into Graves’ disease and thyroid eye disease
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Septerna, Inc. 8-K filings
Get the next SEPN 8-K as it lands
Follow SEPN for push alerts, or ask the research agent what this filing means.